After a period of significant activity in the bio-tech sector, Amgen Inc. (NASDAQ:AMGN) has shown distinct progress. Despite being a turbulent year, several bright spots emerged from their earnings reports. Also, other companies like Bray Capital Advisors and JLB & Associates Inc. have reportedly sold shares in Amgen, along with some other advisory and wealth management firms reducing their holdings in the company. On a promising note, there was an improvement in Key Q4 metrics, exceeding Wall Street estimates. Amgen's earnings and revenues surpassed estimates, with some companies increasing their financial investment in the bio-tech giant.
The company faced a setback with one of its obesity drugs, but is preparing to present at Citi's 2025 Virtual Oncology Leadership Summit. Jim Cramer commented it's 'Absurd That AMGN Stock Sells for 14x Earnings', indicating high valuation of the company. Amgen announced a dividend increase to $2.38, with some share selling ongoing from senior Management. Amgen is set for an exciting 2025, with Robust revenue growth and Strategic expansions in the horizon. Amgen Inc. (NASDAQ:AMGN) is considered a Cheap Quarterly dividend stock worth investing in.
Amgen AMGN News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 22 Feb 2025 11:57:36 GMT - Rating 3 - Innovation 6 - Information 8 - Rumor -2
